NCT07110363View on ClinicalTrials.gov

A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

May 31, 2027

Conditions
Advanced Malignant Solid TumorAdvanced Lung CancerNon-Small Cell Lung CancerSmall Cell Lung Cancer
Interventions
DRUG

BT02

monoclonal antibody injection with intravenous administration every 2 or 3 weeks

Sponsors
All Listed Sponsors
lead

Biotroy Therapeutics

INDUSTRY

NCT07110363 - A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer | Biotech Hunter | Biotech Hunter